Rheumatoid arthritis
Conditions
Interventions
Tripterygium wilfordii group:Tripterygium glycoside tablets alone
Tripterygium + methotrexate group:Tripterygium glycoside tablets + methotrexate tablets
Tripterygium + leflunomide group:Tripterygium glycoside tablets + leflunomide tablets
Tripterygium + hydroxychloroquine group:Tripterygium glycoside tablets + hydroxychloroquine sulfate tablets
Sponsors
Dongzhimen Hospital, Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: ? 18 ~ 65 years old;? 5.1=DAS28 > 3.2;?Men or women who have no reproductive requirements;? Patients who did not participate in any clinical trial within 4 weeks before enrollment;? The patient gives informed consent and signs the informed consent.
Exclusion criteria
Exclusion criteria: ? There are serious organ diseases or mental diseases; ? Patients who can not adhere to medication for 12 weeks due to various reasons; ? Patients with sjogren's syndrome, ankylosing spondylitis, systemic lupus erythematosus, dermatomyositis and other rheumatic diseases; ? Liver and kidney insufficiency; Pregnant or lactating women (breastfeeding); ? Patients with severe gastrointestinal ulcer or active gastrointestinal bleeding; ? Patients with glucocorticoids or biologics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ACR20 response rate;DAS 28-ESR and CRP response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| CDAI;SDAI;VAS;PGA;MDGA;SF-36;HAQ-DI;TNF-a; IL-6;Adverse event rate; | — |
Countries
China
Contacts
Public ContactLV LIU
Dongzhimen Hospital, Beijing University of Chinese Medicine
Outcome results
None listed